Regulus Therapeutics, the microRNA drugs joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, this week disclosed that it is pricing its initial public offering of 11.25 million shares at $4 a share, for a total value of $45 million.

The company said it has also granted the underwriters of the offering the option to buy an additional 1.7 million shares at the $4 offering price. If exercised, the option would boost the value of the IPO to $51.75 million.

The company anticipates going public this week under the symbol “RGLS.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.